3 min read
Measuring What Can't Be Seen: How PTSD Clinical Trials Prove a Drug Works
When an oncology drug is tested, the signal is often brutally clear. A tumor either shrinks on a scan or it does not. A...
Veristat is excited to attend the ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop being sponsored by the ASA Biopharmaceutical Section in cooperation with the FDA Statistical Association.
This conference includes invited sessions co-chaired by statisticians from industry, academia, and the FDA over two days. In addition, short courses on related topics are offered the day prior to the workshop.
Many of the exciting topics that will be discussed at this event include:
To speak with a member of our biostatistical team either at the workshop or anytime that is convenient for you, simply fill out the form on the right hand side of this page.
"Operationalizing A Complex Adaptive Design | Accelerating A Go/No-Go Decision "
A clinical-stage biopharmaceutical company came to Veristat with a complex statistical methodology for running a phase II adaptive design trial with the goal of expediting a go/no-go decision for a specific patient population. The sponsor's challenge was that they didn't fully understand the complex methodology enough to explain it nor design the actual trial.
Learn how and why Veristat was able to implement the design and help the sponsor reach their go/no-go decision quickly.
3 min read
Apr 27, 2026 Veristat Blog
When an oncology drug is tested, the signal is often brutally clear. A tumor either shrinks on a scan or it does not. A...
3 min read
Apr 24, 2026 Veristat Blog
In August 2024, the FDA declined to approve MDMA-assisted therapy for post-traumatic stress disorder. The decision...